Advertisement


Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement



Nov
29
Today In Oncology
CNS Prophylaxis With High-Dose Methotrexate in High-Risk Aggressive B-Cell Lymphoma
Durvalumab May Offer Survival Benefit in Patients With NSCLC and Borderline Performance Status
Urban Environmental Exposures and Incidence of Breast Cancer in North Carolina
Adding Atezolizumab to Perioperative Chemotherapy in Resectable Esophagogastric Cancer
Outcomes With Olaparib in Metastatic Castration-Resistant Prostate Cancer and BRCA Alterations in the PROfound Trial
View More 
Advertisement
© 2023 HSP News Service, L.L.C.
Designed by Harborside